Detalles de la búsqueda
1.
A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the delta variant in kidney transplant recipients
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21266704
2.
Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without Omicron breakthrough infection.
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22277885
3.
B.1.1.7 and B.1.351 SARS-CoV-2 variants display enhanced Spike-mediated fusion
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-448011
4.
Syncytia formation by SARS-CoV-2 infected cells
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-202028
5.
Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4 and BA.5 in patients receiving monoclonal antibodies
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22278699
6.
Humoral Immunity to SARS-CoV-2 and Inferred Protection from Infection in a French Longitudinal Community Cohort
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22275460
7.
Seroneutralization of Omicron BA.1 and BA.2 in patients receiving anti-SARS-CoV-2 monoclonal antibodies.
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22272066
8.
Immunogenicity of BNT162b2 vaccine Against the Alpha and Delta Variants in Immunocompromised Patients
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21261766
9.
Anti-CD38 therapy impairs SARS-CoV-2 vaccine response in multiple myeloma patients
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21261769
10.
Release of infectious virus and cytokines in nasopharyngeal swabs from individuals infected with non-B.1.1.7 or B.1.1.7 SARS-CoV-2 variants.
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21257393
11.
Evolution of human antibody responses up to one year after SARS-CoV-2 infection
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21256823
12.
SARS-CoV-2 Omicron neutralization and risk of infection among elderly after a booster dose of Pfizer vaccine
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22273175
13.
Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-516888
14.
Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-475248
15.
Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-462234
16.
Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-445838
17.
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-430472
18.
Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-472630
19.
Serological reconstruction of COVID-19 epidemics through analysis of antibody kinetics to SARS-CoV-2 proteins
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21252532
20.
SARS-CoV-2 serological analysis of COVID-19 hospitalized patients, pauci-symptomatic individuals and blood donors.
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-20068858